+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR-T Cell Therapy Market Review

  • ID: 4901451
  • Report
  • December 2019
  • Region: Global
  • 59 Pages
  • Kalorama Information
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • bluebird bio, Inc.
  • Celgene Corporation
  • Celyad
  • GlaxoSmithKline
  • Juno Therapeutics
  • MORE

CAR-T cell therapy is a form of immunotherapy that utilizes the body’s own T cells to target and destroy cancer cells. This therapy is a personalized form of treatment, meaning that each patient receives T cells that are geared specifically toward his or her cancer diagnosis. T-cell therapy works by removing existing T cells from a patient and having them grown and modified in a lab. These new T cells are given a gene for a specialized receptor, known as a chimeric antigen receptor (CAR), which allows the cells to specifically attack cancer cells. CAR-T cell therapy has shown effectiveness in eliminating cancer cells, especially for the following diseases:

  • Acute lymphoblastic leukemia (ALL)
  • DLBCL B-cell lymphomas
  • Multiple myeloma

CAR-T Cell Therapy Market Review discusses CAR-T’s impressive revenue growth, which is expected to continue given the effectiveness of the therapy and the projected new users. There are positive factors for the market, though there are limits to growth. Patient volume should increase, though it is likely that the unusually large prices will not sustain over the next five years. The report provides the following market data:

  • CAR-T Market, 2018-2024 ($millions)
  • CAR-T Market Share, 2019 (%)
  • CAR-T Market Regional Breakout, 2019 (%)

CAR-T Cell Therapy Market Review discusses CAR-T therapy market trends, issues, and recent developments, including the following:

  • Global Cancer Burden
  • Complexity of the CARs Manufacturing Process
  • Diseases Treated with CAR-T
  • Study Shows Yescarta Increases Longevity
  • CRS and Other Side Effects
  • China CAR-T Competition
  • Indian CAR-T Competition
  • “Off-the-Shelf” CAR-T Therapies in Development
  • Competing Therapy in Development

Also noted in the report are selected CAR-T therapies in development, an effort to capture current media coverage of CAR-T trials.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • bluebird bio, Inc.
  • Celgene Corporation
  • Celyad
  • GlaxoSmithKline
  • Juno Therapeutics
  • MORE

1. Executive Summary

  • Introduction
  • CAR-T Therapy Market Trends, Issues, and Recent Developments
  • CAR-T Therapy Market
  • Companies in the Market

2. CAR-T Cell Therapy Market

FDA-Approved CAR-T Therapies: Yescarta and Kymriah

  • Yescarta
  • Kymriah
  • Table 2-1: FDA-Approved CAR-T Therapies
  • CAR-T Therapy Market Trends/Issues
  • Global Cancer Burden
  • Figure 2-1: Global Cancer Incidence Trends, 2010-2040
  • Complexity of the CARs Manufacturing Process
  • Diseases Treated with CAR-T

Recent Market Developments

  • Study Shows Yescarta Increases Longevity
  • CRS and Other Side Effects
  • China CAR-T Competition
  • Indian CAR-T Competition
  • “Off-the-Shelf” CAR-T Therapies in Development
  • A Competing Therapy in Development

Selected CAR-T Therapies in Development

  • Table 2-2: Selected CAR-T Therapies in Development
  • KTE-X19
  • liso-cel
  • C-CAR088
  • IBI326 (Innovent)/CT103A (IASO BIO)
  • bb21217
  • MB-107
  • ICTCAR014
  • bb2121
  • JNJ-682284528 (JNJ-4528)
  • CT053
  • MB-101 (IL-13Ra2)
  • MB-108 (oncolytic virus C134)
  • CYAD-01
  • BAFF-R CAR-T
  • MB-105 (PSCA)
  • MB-102 (CD123)
  • MB-103 (HER2)
  • P-BCMA-101
  • LCAR-B38M
  • JCARH125
  • MCARH171
  • CYAD-101
  • MB-106 (CD20)
  • MB-104 (CS1)
  • AMG 119
  • ATA2271
  • AUTO1
  • AUTO3

CAR-T Market Analysis

  • Figure 2-2: CAR-T Market, 2018-2024 ($millions)
  • Market Share
  • Figure 2-3: CAR-T Market Share, 2019 (%)
  • Regional Breakout
  • Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)

3 Companies in the Market

  • AbbVie, Inc.
  • Company Summary
  • Scripps Research Institute Deal
  • Tyrosine Kinase Inhibitors Market
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Company Summary
  • bb2121
  • bb21217
  • bb2121
  • Bristol-Myers Squibb Company
  • Company Summary
  • BMS Acquires Celgene
  • Monoclonal Antibodies Market
  • Cancer Kinase Inhibitor Market
  • CARsgen Therapeutics
  • Celgene Corporation
  • Company Summary
  • Collaboration with Immatics Biotechnologies
  • Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
  • Celgene Buys JAK2 Inhibitor Maker
  • Cellectis, Inc.
  • Pfizer
  • Servier
  • Celyad
  • CYAD-01
  • CYAD-101
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Gracell Biotechnology
  • Immune Therapeutics
  • CAR-T
  • Innovative Cellular Therapeutics
  • ICTCAR014
  • Juno Therapeutics
  • Selected CAR-T Therapies in Development
  • Collaboration with Editas Medicine
  • Kite Pharma, Inc.
  • KTE-X19
  • Yescarta
  • Mustang Bio
  • Novartis International AG
  • Company Summary
  • Kymriah
  • Intellia Therapeutics
  • Other Company Activity
  • Pfizer, Inc.
  • Sorrento Therapeutics
  • ZIOPHARM Oncology, Inc.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie, Inc.
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellectis, Inc.
  • Celyad
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Immune Therapeutics
  • Innovative Cellular Therapeutics
  • Juno Therapeutics
  • Kite Pharma, Inc.
  • Mustang Bio
  • Novartis International AG
  • Pfizer, Inc.
  • Sorrento Therapeutics
  • ZIOPHARM Oncology, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll